SCHEMBL18824760

SCHEMBL18824760

CN(C)C1CCN(c2ccc(-c3ccc4ncc5c(c4c3)n([C@@H]3CCCOC3)c(=O)n5C)cn2)CC1

nearest known ligand 0.67

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
▸ ATM Q13315 19/20 0.67
▸ ATR Q13535 8/20 0.67
▸ MTOR P42345 16/20 0.66
▸ PIK3CA P42336 14/20 0.66
▸ KCNH2 Q12809 1/20 0.66

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18843780 1.00 ATM (0.67) ATMATRMTORPIK3CAKCNH2
SCHEMBL18824788 0.95 ATM (0.68) ATMATRMTORPIK3CAKCNH2
SCHEMBL18843768 0.95 ATM (0.68) ATMATRMTORPIK3CAKCNH2
SCHEMBL18843770 0.95 ATM (0.68) ATMATRMTORPIK3CAKCNH2
SCHEMBL18824953 0.95 ATM (0.68) ATMATRMTORPIK3CAKCNH2
SCHEMBL18843812 0.93 ATM (0.68) ATMATRMTORPIK3CAKCNH2
SCHEMBL18824702 0.93 ATM (0.68) ATMATRMTORPIK3CAKCNH2
SCHEMBL18824720 0.93 ATM (0.65) ATMATRMTORPIK3CAKCNH2
SCHEMBL18824793 0.91 ATM (0.67) ATMATRMTORPIK3CAKCNH2
SCHEMBL18843769 0.91 ATM (0.70) ATMATRMTORPIK3CAKCNH2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180280377-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA UK LIMITED (GB) 2018-10-04 — — US claimed
EP-3370722-A1 IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2018-09-12 — — EP claimed
WO-2017076898-A1 IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2017-05-11 — — WO claimed
US-20230256110-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR ASTRAZENECA UK LIMITED (GB) 2023-08-17 — — US disclosed
CN-116194109-A Combination of antibody-drug conjugate and ATM inhibitor 阿斯利康(英国)有限公司 2023-05-30 — — CN disclosed
EP-4171651-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR AstraZeneca UK Limited (GB) 2023-05-03 — — EP disclosed
WO-2021260580-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR ASTRAZENECA UK LIMITED (GB) 2021-12-30 — — WO disclosed
US-20180280377-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ASTRAZENECA UK LIMITED (GB) 2018-10-04 — — US disclosed
EP-3370722-A1 IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER Astrazeneca AB (SE) 2018-09-12 — — EP disclosed
WO-2017076898-A1 IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2017-05-11 — — WO disclosed
WO-2017076898-A1 IMIDAZO[4,5-C]QUINOLIN-2-ONE COMPOUNDS AND THEIR USE IN TREATING CANCER ASTRAZENECA AB (SE) 2017-05-11 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230256110-A1 COMBINATION OF ANTIBODY-DRUG CONJUGATE AND ATM INHIBITOR ATM, CHEK2, ERBB2 ATM 1/4885ATR 7/4885MTOR 506/4885
US-20180280377-A1 Imidazo[4,5-c]quinolin-2-one Compounds and Their Use in Treating Cancer ATM, BRCA1, CHEK2 ATM 1/4885ATR 7/4885MTOR 1304/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback